GlobeNewswire by notified

Correction: TGS Q3 2021 Earnings Update

Share

OSLO, Norway (8 October 2021) - Based on preliminary reporting from operating units, TGS management expects net IFRS revenues* for the third quarter of 2021 to be approximately USD 200 million, compared to USD 58 million in Q3 2020. Net segment revenues* are expected to be approximately USD 61 million, compared to USD 81 million in Q3 2020.

Kristian Johansen, CEO at TGS, commented: "The market conditions for multi-client seismic data continues to be very challenging. E&P companies’ 2021 budgets do not allow for much spending beyond what was committed at the start of the year, meaning that the recent oil price increases so far have had little impact on spending levels. However, with the current oil price, the value proposition of exploration for new oil and gas resources is very attractive. As such, we remain optimistic that spending on exploration related data and services will improve as E&P companies are entering a new budget cycle with lower levels of legacy commitments. Meanwhile, the financial position stays healthy with approximately USD 200 million of cash and no interest-bearing debt on the balance sheet.”

TGS will report the Q3 2021 financial results on 28 October 2021.

* Following notification from The Financial Supervisory Authority of Norway (Finanstilsynet) TGS will from 2021 increase emphasis on IFRS in its financial reporting to the market. The Company will continue to provide segment information for historic comparison and as alternative performance measures of the business as such measures are commonly used throughout the industry, and TGS' management believes they better reflect the ongoing activity in projects-in-progress. The main difference between IFRS and Segment reporting relates to revenue recognition. Under IFRS revenue recognition generally is deferred until project completion and delivery to the customer when performance obligations are met. Under Segment reporting, net revenue from projects-in-progress is recognized based on Percentage of Completion (POC). Revenue recognition has subsequent effects on the recognition of amortization of the multi-client library. Please see the annual report for a complete description of the Company's accounting principles.

Adjustments between preliminary IFRS and Segment revenue numbers for Q3 2021:

Preliminary IFRS reported revenue: USD 200 million
- Revenue recognized from performance obligations met during Q3 for completed projects: USD 163 million
+ Revenue recognized under POC during Q1: USD 24 million
= Preliminary net segment reported revenue: USD 61 million

About TGS
TGS provides scientific data and intelligence to companies active in the energy sector. In addition to a global, extensive and diverse energy data library, TGS offers specialized services such as advanced processing and analytics alongside cloud-based data applications and solutions.

Forward Looking Statement
All statements in this press release other than statements of historical fact are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may not prove accurate. These factors include TGS' reliance on a cyclical industry and principal customers, TGS' ability to continue to expand markets for licensing of data, and TGS' ability to acquire and process data product at costs commensurate with profitability, as well as volatile market conditions, which have been exacerbated by the COVID-19 pandemic and the severe drop in oil prices.  Actual results may differ materially from those expected or projected in the forward-looking statements. TGS undertakes no responsibility or obligation to update or alter forward-looking statements for any reason.

For further information, please contact:

Sven Børre Larsen
Chief Financial Officer 
Tel: +47 90 94 36 73
E-mail: investor@tgs.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Vaisala's Interim Report January–March 2024 to be published on May 3, 202416.4.2024 15:00:00 CEST | Press release

Vaisala Corporation Press release April 16, 2024, at 4:00 p.m. (EEST) Vaisala's Interim Report January–March 2024 to be published on May 3, 2024 Vaisala Corporation will publish its Interim Report January–March 2024 on Friday, May 3, 2024, at about 9:00 a.m. (Finnish time). The release will be available at vaisala.com/investors. The President and CEO's presentation will be published by 1:00 p.m. on the same day at vaisala.com/investors. Audiocast and teleconference An audiocast and a conference call for analysts, investors and media will be held in English on the same day starting at 1:00 p.m. (Finnish time). You can participate in the live audiocast via following link: https://vaisala.videosync.fi/q1-2024 Questions may be presented by participating in the teleconference. You can access the teleconference by registering on the link below. After the registration, you will receive an email with the dial-in numbers and a conference ID. https://palvelu.flik.fi/teleconference/?id=50048551 A

Calibre Announces Closing of C$115 Million Financing16.4.2024 14:41:32 CEST | Press release

Not for distribution to U.S. news wire services or dissemination in the United States. VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Calibre Mining Corp. (TSX: CXB; OTCQX: CXBMF) (“Calibre” or the “Company”) is pleased to announce that it has closed its previously announced bought deal financing (the “Offering”) for aggregate gross proceeds of C$115,147,200. Pursuant to the Offering, a total of 68,540,000 common shares of the Company (“Common Shares”), including 8,940,000 Common Shares issued pursuant to the exercise in full of the over-allotment option, were sold at a price of C$1.68 per Common Share. The Common Shares issued pursuant to the Offering were offered by way of a short form prospectus filed in all provinces and territories of Canada, except Québec. The Offering was conducted through a syndicate of underwriters comprised of BMO Capital Markets, as lead underwriter, and Canaccord Genuity Corp., Scotia Capital Inc., Haywood Securities Inc. and Cormark Securi

KALLELSE TILL ÅRSSTÄMMA I CORLINE BIOMEDICAL AB (PUBL)16.4.2024 14:40:36 CEST | Pressemelding

Aktieägarna i Corline Biomedical AB (publ), org.nr 556417-0743 ("Bolaget"), kallas härmed till årsstämma onsdagen den 15 maj 2024 klockan 14.00 i Advokatfirman Lindahls lokaler på Vaksalagatan 10 i Uppsala. Anmälan m.m. Aktieägare som önskar delta i årsstämman måste: dels vara registrerad i eget namn (inte förvaltarregistrerad) i den av Euroclear Sweden AB förda aktieboken måndagen den 6 maj 2024,dels anmäla sitt deltagande så att anmälan är Bolaget till handa senast måndagen den 13 maj 2024 (den s.k. avstämningsdagen). Anmälan kan göras via e-post till olle.sward.brattstrom@lindahl.se eller per post till adressen Advokatfirman Lindahl KB, att. Olle Swärd Brattström, Box 1203, 751 42 Uppsala. Vid anmälan uppges aktieägarens namn, person- eller organisationsnummer (eller motsvarande) och gärna adress, telefonnummer, aktieinnehav, uppgift om eventuella biträden (högst två), samt i förekommande fall uppgift om ställföreträdare eller ombud. Förvaltarregistrerade aktier Aktieägare som låtit

Resolutions of Marimekko Corporation’s Annual General Meeting and the Board of Directors’ constitutive meeting16.4.2024 14:40:00 CEST | Press release

Marimekko Corporation, Stock Exchange Release 16 April 2024 at 3.40 p.m. Resolutions of Marimekko Corporation’s Annual General Meeting and the Board of Directors’ constitutive meeting At Marimekko Corporation’s Annual General Meeting (the AGM), held today, and at the subsequent constitutive meeting of the Board of Directors, the following resolutions were passed. A. RESOLUTIONS OF THE ANNUAL GENERAL MEETING Adoption of the financial statements Marimekko Corporation’s income statement and balance sheet and the consolidated income statement and balance sheet for 2023 were adopted. Payment of dividend The AGM approved the Board of Directors’ proposal to distribute a dividend of EUR 0.37 per share for the financial year 2023. The dividend will be paid on 25 April 2024 to shareholders who are registered on the dividend payout record date of 18 April 2024 in the company’s shareholder register held by Euroclear Finland Ltd on behalf of the Board of Directors of the company. Discharge from lia

Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer16.4.2024 14:00:00 CEST | Press release

Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion’s Board of Directors SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development, announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer. Dr. Khan will lead Recursion’s research and development, and build its emerging commercial capabilities. She has also been appointed to Recursion’s Board of Directors. “Najat brings a unique blend of leadership in biological, chemical, and medical sciences, data science, and business,” said Chris Gibson, Co-Founder and CEO of Recursion. “More importantly, she has a vision and passion for transforming drug discovery and development that complements ours and she has a strong sense of urgency to accelerate the industry’s f

HiddenA line styled icon from Orion Icon Library.Eye